Neridronic acid for treating complex regional pain syndrome
Osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising selecting a human being having CRPS triggered by bone fracture and administering neridronic acid or a pharmaceutically acceptable salt thereof to the human being, wherein the treatment is effective in reducing pain.
2. The method of claim 1 , wherein the CRPS is CRPS type I.
3. The method of claim 1 , wherein the neridronic acid is in a salt form.
4. The method of claim 1 , wherein the neridronic acid is administered intravenously.
5. The method of claim 1 , wherein the neridronic acid is administered orally.
6. The method of claim 5 , wherein a total of about 50 mg to about 500 mg of the neridronic acid is administered daily.
7. The method of claim 5 , wherein a total of about 100 mg to about 500 mg of the neridronic acid is administered daily.
8. The method of claim 5 , wherein a total of about 150 mg to about 300 mg of the neridronic acid is administered daily.
9. The method of claim 1 , wherein the neridronic acid is administered parenterally.
10. The method of claim 9 , wherein a total of about 5 mg to about 500 mg of the neridronic acid is administered within one month.
11. The method of claim 9 , wherein a total of about 5 mg to about 200 mg of the neridronic acid is administered within one month.
12. The method of claim 9 , wherein each dose contains about 10 mg to about 150 mg of the neridronic acid.
13. The method of claim 9 , wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered within one month.
14. The method of claim 1 , wherein a total of about 100 mg to about 600 mg of the neridronic acid is administered.
15. The method of claim 1 , wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered.
16. The method of claim 4 , wherein each dose contains about 10 mg to about 150 mg of the neridronic acid.
17. The method of claim 4 , wherein each dose contains about 100 mg of the neridronic acid.
18. The method of claim 17 , wherein the neridronic acid is administered at least four times.
19. The method of claim 4 , wherein each dose contains about 50 mg to about 65 mg of the neridronic acid.
20. The method of claim 19 , wherein the neridronic acid is administered about every three days.
21. The method of claim 5 , wherein each dose contains about 100 mg of the neridronic acid.
22. The method of claim 3 , wherein each dose contains an equivalent of about 50 mg to about 60 mg of the neridronic acid in an acid form.
23. The method of claim 1 , wherein the neridronic acid is administered about once daily to about once weekly.
24. The method of claim 1 , wherein the neridronic acid is administered in a single or in divided doses.
25. The method of claim 17 , wherein about four doses of about 100 mg of the neridronic acid are administered.
26. The method of claim 1 , wherein the neridronic acid is administered weekly for about four to about six weeks.
27. The method of claim 1 , wherein the human being is at least 18 years of age.
28. The method of claim 27 , wherein the human being is at least 40 years of age.
29. The method of claim 27 , wherein the human being has a baseline pain intensity score of at least 4 on the 0-10 Numeric Rating Scale.
30. The method of claim 1 , wherein the CRPS is CRPS type II.